Clinical Trials
Numerous clinical trials spanning Phase 1 through Phase 4 evaluate the therapeutic profile and bioequivalence of salmeterol, primarily targeting asthma, exercise-induced asthma, chronic obstructive pulmonary disease, and abdominal contour defects. Featuring statuses ranging from active recruitment and completed studies to withdrawn or terminated protocols, these investigations are supported by major pharmaceutical enterprises and prominent academic institutions. Together, these studies serve to characterize salmeterol's safety and efficacy across diverse patient cohorts.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05776927 | RECRUITING | Asthma |
Novartis Pharmaceuticals |
2026-08-04 | PHASE3 |
| NCT06676319 | ACTIVE_NOT_RECRUITING | Asthma |
Sanofi |
2024-11-07 | PHASE2 |
| NCT01225913 | RECRUITING | Asthma |
Gelb, Arthur F., M.D. |
2007-10 | PHASE4 |
| NCT06657547 | RECRUITING | Healthy |
University of Copenhagen |
2024-10-31 | |
| NCT06655012 | RECRUITING | Healthy |
University of Copenhagen |
2024-10-31 | |
| NCT06654986 | RECRUITING | Healthy |
University of Copenhagen |
2024-10-31 | |
| NCT06040268 | RECRUITING | Altitude Edema |
University of Colorado, Denver |
2023-12-12 | PHASE1; PHASE2 |
| NCT04503460 | UNKNOWN | Asthma |
Imperial College London |
2021-07-23 | PHASE4 |
| NCT05748977 | UNKNOWN | Copd |
Assiut University |
2023-02-20 | EARLY_PHASE1 |
| NCT04655508 | TERMINATED | Stem Cell Transplant Complications; Respiratory Disease; Bronchiolitis Obliterans |
Assistance Publique - Hôpitaux de Paris |
2021-05-21 | PHASE3 |
| NCT06025214 | UNKNOWN | Bioequivalence |
Respirent Pharmaceuticals Co Ltd. |
2023-08-22 | PHASE1 |
| NCT05982990 | UNKNOWN | Bioequivalence |
Respirent Pharmaceuticals Co Ltd. |
2023-08-01 | PHASE1 |
| NCT05664061 | UNKNOWN | Asthma |
Respirent Pharmaceuticals Co Ltd. |
2023-01-30 | PHASE3 |
| NCT05697003 | UNKNOWN | Bioequivalence |
Respirent Pharmaceuticals Co Ltd. |
2023-02-17 | PHASE1 |
| NCT03363503 | TERMINATED | COPD |
Neutec Ar-Ge San ve Tic A.Ş |
2018-04-13 | PHASE4 |
| NCT04677959 | COMPLETED | Asthma |
Teva Branded Pharmaceutical Products R&D, Inc. |
2021-02-16 | PHASE4 |
| NCT05085587 | UNKNOWN | Bioequivalence; Asthma |
Respirent Pharmaceuticals Co Ltd. |
2021-10-01 | PHASE1 |
| NCT05085587 | Unknown status | Bioequivalence|Asthma |
Respirent Pharmaceuticals Co Ltd.|Becro Ltd. |
2021-10-01 | Phase 1 |
| NCT04503460 | Recruiting | Asthma |
Imperial College London|European Research Council |
2021-07-23 | Phase 4 |
| NCT04746040 | UNKNOWN | Bioequivalence; Asthma |
Respirent Pharmaceuticals Co Ltd. |
2021-01-18 | PHASE1 |
| NCT04564456 | COMPLETED | Bioequivalence |
Respirent Pharmaceuticals Co Ltd. |
2020-09-22 | PHASE1 |
| NCT04546256 | COMPLETED | Bioequivalence |
Respirent Pharmaceuticals Co Ltd. |
2020-09-01 | PHASE1 |
| NCT04462822 | COMPLETED | Bioequivalence |
Respirent Pharmaceuticals Co Ltd. |
2020-08-24 | PHASE1 |
| NCT04466176 | COMPLETED | Bioequivalence |
Respirent Pharmaceuticals Co Ltd. |
2020-07-01 | PHASE1 |
| NCT03395002 | COMPLETED | COPD |
Neutec Ar-Ge San ve Tic A.Ş |
2018-03-22 | PHASE4 |
| NCT03387241 | UNKNOWN | Asthma |
Mundipharma (China) Pharmaceutical Co. Ltd |
2017-06-02 | PHASE3 |
| NCT03394989 | COMPLETED | Bronchial Asthma |
Cipla Ltd. |
2018-10-17 | PHASE3 |
| NCT03745261 | UNKNOWN | Pulmonary Disease, Chronic Obstructive |
Henan University of Traditional Chinese Medicine |
2018-06-20 | PHASE3 |
| NCT03756883 | COMPLETED | Asthma |
Actavis Inc. |
2018-12-03 | PHASE3 |
| NCT04124094 | COMPLETED | Bioequivalence |
Respirent Pharmaceuticals Co Ltd. |
2019-10-01 | PHASE1 |
| NCT03535870 | COMPLETED | Asthma |
West-Ward Pharmaceutical |
2018-04-26 | |
| NCT03269318 | TERMINATED | Asthma |
Brighton and Sussex University Hospitals NHS Trust |
2017-07-01 | PHASE4 |
| NCT03676413 | COMPLETED | Asthma |
Respirent Pharmaceuticals Co Ltd. |
2018-10-02 | PHASE3 |
| NCT02972476 | COMPLETED | Chronic Obstructive Pulmonary Disease |
University of Dundee |
2016-12 | PHASE4 |
| NCT03158311 | COMPLETED | Asthma |
Novartis Pharmaceuticals |
2018-02-05 | PHASE3 |
| NCT02758873 | COMPLETED | Asthma |
University of Sussex |
2016-02 | |
| NCT03975166 | COMPLETED | Bioequivalence |
Respirent Pharmaceuticals Co Ltd. |
2019-05-21 | PHASE1 |
| NCT02477397 | UNKNOWN | COPD |
University Medical Center Groningen |
2015-05-01 | PHASE3 |
| NCT02571777 | COMPLETED | Asthma |
Novartis Pharmaceuticals |
2015-12-08 | PHASE3 |
| NCT03562923 | UNKNOWN | Asthma |
Amneal Ireland Limited |
2018-10 | PHASE3 |
| NCT03894280 | COMPLETED | Bioequivalence |
Respirent Pharmaceuticals Co Ltd. |
2019-03-12 | PHASE1 |
| NCT03240575 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
Boehringer Ingelheim |
2017-08-14 | PHASE4 |
| NCT02980133 | COMPLETED | Asthma |
Teva Branded Pharmaceutical Products R&D, Inc. |
2016-12-28 | PHASE3 |
| NCT03387852 | COMPLETED | Asthma |
Sanofi |
2018-03-12 | PHASE2 |
| NCT02924688 | COMPLETED | Asthma |
GlaxoSmithKline |
2016-10-13 | PHASE3 |
| NCT03207243 | COMPLETED | Asthma |
GlaxoSmithKline |
2017-09-14 | PHASE2 |
| NCT03820180 | COMPLETED | Bioequivalence |
Respirent Pharmaceuticals Co Ltd. |
2019-01-23 | PHASE1 |
| NCT04195867 | COMPLETED | Healthy Volunteers |
Parc de Salut Mar |
2018-11-20 | PHASE1 |
| NCT03755544 | Completed | Asthma|Chronic Obstructive Pulmonary Disease |
Orion Corporation Orion Pharma |
2019-01-16 | -- |
| NCT03751202 | COMPLETED | Bioequivalence |
Respirent Pharmaceuticals Co Ltd. |
2018-11-20 | PHASE1 |
| NCT02554786 | COMPLETED | Asthma |
Novartis Pharmaceuticals |
2015-12-29 | PHASE3 |
| NCT03461627 | UNKNOWN | Asthma |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
2017-04-01 | PHASE3 |
| NCT03063086 | COMPLETED | Asthma |
Novartis Pharmaceuticals |
2017-01-21 | PHASE2 |
| NCT03034915 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2017-06-16 | PHASE4 |
| NCT03055988 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
Boehringer Ingelheim |
2017-03-29 | PHASE4 |
| NCT02573233 | COMPLETED | Asthma |
Sanofi |
2016-01-27 | PHASE2 |
| NCT03238482 | COMPLETED | Asthma |
Orion Corporation, Orion Pharma |
2017-08-16 | PHASE1 |
| NCT02757209 | COMPLETED | Asthma; COPD |
Consorzio Futuro in Ricerca |
2016-04 | |
| NCT02446418 | COMPLETED | Asthma |
GlaxoSmithKline |
2015-07-09 | PHASE3 |
| NCT02603393 | COMPLETED | Chronic Obstructive Pulmonary Disease (COPD) |
Novartis Pharmaceuticals |
2015-11-20 | PHASE4 |
| NCT03005717 | COMPLETED | Submental Fat |
Neothetics, Inc |
2016-12-22 | PHASE2 |
| NCT02024204 | COMPLETED | Lung Diseases; Medication Compliance |
NYU Langone Health |
2014-04-09 | |
| NCT02516592 | COMPLETED | COPD |
Novartis Pharmaceuticals |
2015-10-13 | PHASE4 |
| NCT02491970 | TERMINATED | Asthma |
Mundipharma Korea Ltd |
2015-08-31 | PHASE4 |
| NCT02061280 | COMPLETED | Asthma |
Nemours Children's Clinic |
2013-10 | PHASE4 |
| NCT02270424 | UNKNOWN | Pulmonary Disease, Chronic Obstructive |
Henan University of Traditional Chinese Medicine |
2014-10 | PHASE3 |
| NCT02301975 | COMPLETED | Asthma |
GlaxoSmithKline |
2015-03-01 | PHASE3 |
| NCT03060044 | COMPLETED | Asthma |
Orion Corporation, Orion Pharma |
2016-07 | PHASE1 |
| NCT02496715 | WITHDRAWN | Asthma |
Actavis Inc. |
2015-09 | PHASE3 |
| NCT02556073 | UNKNOWN | Asthma |
Taipei Veterans General Hospital, Taiwan |
2014-08 | |
| NCT02558088 | COMPLETED | Pharmacokinetics in Healthy Young Men |
University of Copenhagen |
2014-09 | PHASE4 |
| NCT02113436 | COMPLETED | Asthma |
GlaxoSmithKline |
2014-05-01 | PHASE4 |
| NCT02680561 | COMPLETED | Asthma |
Teva Branded Pharmaceutical Products R&D, Inc. |
2016-04 | PHASE1 |
| NCT02195375 | COMPLETED | Chronic Obstructive Pulmonary Disease |
Mundipharma Research Limited |
2014-09 | PHASE2; PHASE3 |
| NCT01355991 | UNKNOWN | Spinal Cord Injury |
James J. Peters Veterans Affairs Medical Center |
2011-08 | PHASE1 |
| NCT02388373 | COMPLETED | Asthma |
Research in Real-Life Ltd |
2014-07 | PHASE4 |
| NCT02415179 | COMPLETED | Asthma |
Mahidol University |
2015-05 | |
| NCT02055352 | COMPLETED | Chronic Obstructive Pulmonary Disease |
Novartis Pharmaceuticals |
2014-05-30 | PHASE4 |
| NCT02546349 | UNKNOWN | COPD |
Taipei Veterans General Hospital, Taiwan |
2014-07 | PHASE4 |
| NCT01462344 | COMPLETED | Asthma |
GlaxoSmithKline |
2011-11-17 | PHASE4 |
| NCT02649478 | COMPLETED | Asthma |
Roxane Laboratories |
2014-08 | |
| NCT02162485 | COMPLETED | Asthma |
Orion Corporation, Orion Pharma |
2014-06 | PHASE1 |
| NCT01437995 | COMPLETED | Asthma |
Johns Hopkins University |
2012-03 | PHASE4 |
| NCT02141854 | COMPLETED | Asthma |
Teva Branded Pharmaceutical Products R&D, Inc. |
2014-06 | PHASE3 |
| NCT01762800 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2013-02 | PHASE4 |
| NCT01782326 | COMPLETED | Chronic Obstructive Pulmonary Disease (COPD) |
Novartis Pharmaceuticals |
2013-07 | PHASE3 |
| NCT02139644 | COMPLETED | Asthma |
Teva Branded Pharmaceutical Products R&D, Inc. |
2014-06 | PHASE3 |
| NCT02175771 | COMPLETED | Persistent Asthma |
Teva Branded Pharmaceutical Products R&D, Inc. |
2014-07 | PHASE3 |
| NCT02245672 | COMPLETED | Asthma |
Mylan Pharma UK Ltd. |
2014-10 | PHASE3 |
| NCT02437604 | COMPLETED | Asthma |
Teva Branded Pharmaceutical Products R&D, Inc. |
2015-05 | PHASE1 |
| NCT01475721 | COMPLETED | Asthma |
GlaxoSmithKline |
2011-11-18 | PHASE4 |
| NCT01853787 | COMPLETED | Chronic Obstructive Pulmonary Disease (COPD) |
University of Milan |
2014-07 | PHASE4 |
| NCT02218762 | WITHDRAWN | Asthma |
GlaxoSmithKline |
2014-10 | PHASE1 |
| NCT01794780 | COMPLETED | COPD |
Novartis Pharmaceuticals |
2013-02-05 | PHASE4 |
| NCT02260492 | COMPLETED | Asthma |
Oriel Therapeutics |
2014-09 | PHASE1 |
| NCT01696214 | COMPLETED | Asthma |
University of California, San Diego |
2012-10 | PHASE4 |
| NCT01836016 | UNKNOWN | Pulmonary Disease, Chronic Obstructive |
Henan University of Traditional Chinese Medicine |
2013-05 | PHASE3 |
| NCT01978145 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2013-11-14 | PHASE3 |
| NCT01978119 | COMPLETED | Asthma |
GlaxoSmithKline |
2013-11-06 | PHASE3 |
| NCT01969721 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
Boehringer Ingelheim |
2013-10 | PHASE3 |
| NCT01892787 | COMPLETED | Asthma |
University of Dundee |
2013-07 | PHASE4 |
| NCT02232087 | COMPLETED | Healthy |
Kindeva Drug Delivery |
2014-07 | PHASE1 |
| NCT02466503 | COMPLETED | Asthma; Chronic Obstructive Pulmonary Disease (COPD) |
Intech Biopharm Ltd. |
2014-08 | PHASE1 |
| NCT01860066 | WITHDRAWN | Chronic Obstructive Pulmonary Disease |
Novartis Pharmaceuticals |
2013-12 | PHASE3 |
| NCT01834885 | WITHDRAWN | Chronic Obstructive Pulmonary Disease |
Novartis Pharmaceuticals |
2013-12 | PHASE3 |
| NCT01908140 | COMPLETED | Chronic Obstructive Pulmonary Disease (COPD) |
AstraZeneca |
2013-09 | PHASE3 |
| NCT02466347 | COMPLETED | Asthma; Chronic Obstructive Pulmonary Disease (COPD) |
Intech Biopharm Ltd. |
2014-06 | PHASE1 |
| NCT01907334 | COMPLETED | Asthma |
University of Florida |
2013-08 | PHASE4 |
| NCT02094274 | COMPLETED | Asthma |
Almirall, S.A. |
2013-11 | PHASE1 |
| NCT01757015 | WITHDRAWN | Chronic Obstructive Pulmonary Disease |
Novartis Pharmaceuticals |
2013-04 | PHASE3 |
| NCT02045953 | COMPLETED | Asthma |
GlaxoSmithKline |
2014-01-29 | PHASE1 |
| NCT01570478 | COMPLETED | Asthma |
Chiesi Farmaceutici S.p.A. |
2012-07 | PHASE3 |
| NCT01555138 | COMPLETED | Chronic Obstructive Pulmonary Disease |
Novartis Pharmaceuticals |
2012-02 | PHASE4 |
| NCT01709903 | COMPLETED | Chronic Obstructive Pulmonary Disease |
Novartis Pharmaceuticals |
2012-11 | PHASE3 |
| NCT01879410 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2013-06-13 | PHASE3 |
| NCT01513460 | COMPLETED | Chronic Obstructive Pulmonary Disease |
Novartis Pharmaceuticals |
2012-04 | PHASE3 |
| NCT01751113 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2013-02 | PHASE4 |
| NCT02215122 | COMPLETED | Asthma; COPD |
Mylan Pharma UK Ltd. |
2013-10 | PHASE1 |
| NCT01822899 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2013-04-04 | PHASE3 |
| NCT01817764 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2013-03-01 | PHASE3 |
| NCT01890863 | COMPLETED | Asthma |
GlaxoSmithKline |
2013-08-05 | PHASE1 |
| NCT01636076 | COMPLETED | COPD |
Novartis Pharmaceuticals |
2012-11 | PHASE2 |
| NCT01117116 | COMPLETED | Asthma |
National Jewish Health |
2010-03 | |
| NCT01856621 | COMPLETED | Asthma |
Orion Corporation, Orion Pharma |
2013-05 | PHASE1 |
| NCT01772147 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2013-01 | PHASE3 |
| NCT01795664 | COMPLETED | Asthma |
FLUIDDA nv |
2013-03 | PHASE3 |
| NCT01772134 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2013-01-01 | PHASE3 |
| NCT00975195 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
Boehringer Ingelheim |
2009-02 | PHASE4 |
| NCT01290874 | COMPLETED | Asthma |
Brigham and Women's Hospital |
2011-03-30 | PHASE3 |
| NCT01706328 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2012-10-15 | PHASE3 |
| NCT01802723 | COMPLETED | Periumbilical Subcutaneous Adipose Tissue Reduction |
Neothetics, Inc |
2013-02 | PHASE2 |
| NCT01361984 | UNKNOWN | Chronic Obstructive Pulmonary Disease; COPD; Emphysema; Chronic Bronchitis |
University of California, Los Angeles |
2011-06 | PHASE4 |
| NCT01772368 | COMPLETED | Asthma |
Teva Branded Pharmaceutical Products R&D, Inc. |
2013-01 | PHASE2 |
| NCT01766843 | COMPLETED | Asthma |
Orion Corporation, Orion Pharma |
2013-01 | PHASE1 |
| NCT01213693 | COMPLETED | Chronic Obstructive Pulmonary Disease |
Università degli Studi di Ferrara |
2009-05 | |
| NCT01172808 | COMPLETED | Asthma |
Boehringer Ingelheim |
2010-08 | PHASE3 |
| NCT01536587 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2012-07 | PHASE4 |
| NCT01172821 | COMPLETED | Asthma |
Boehringer Ingelheim |
2010-08 | PHASE3 |
| NCT01712451 | COMPLETED | Abdominal Contour Defects |
Neothetics, Inc |
2011-08 | PHASE2 |
| NCT01391559 | COMPLETED | Chronic Obstructive Pulmonary Disease |
Dartmouth-Hitchcock Medical Center |
2011-07 | |
| NCT01312961 | COMPLETED | Asthma |
Sanofi |
2011-03 | PHASE2 |
| NCT01540708 | COMPLETED | Asthma |
GlaxoSmithKline |
2012-01-16 | PHASE1 |
| NCT01344655 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
Chiesi Farmaceutici S.p.A. |
2011-04 | PHASE4 |
| NCT01657487 | UNKNOWN | Percentage of Annual Acute Exacerbation; Quality of Life |
Far Eastern Memorial Hospital |
2010-04 | PHASE4 |
| NCT01393145 | WITHDRAWN | Chronic Obstructive Pulmonary Disease; COPD |
Ache Laboratorios Farmaceuticos S.A. |
2011-08 | PHASE3 |
| NCT02782312 | COMPLETED | Bronchiectasis |
Shanghai Pulmonary Hospital, Shanghai, China |
2011-06 | PHASE4 |
| NCT01564199 | COMPLETED | Healthy Volunteer Study |
Orion Corporation, Orion Pharma |
2012-04 | PHASE1 |
| NCT01321463 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
Pfizer |
2011-05 | PHASE2 |
| NCT01209715 | WITHDRAWN | COPD |
University of Miami |
2010-10 | PHASE2 |
| NCT01110200 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2010-04-30 | PHASE4 |
| NCT01245569 | COMPLETED | Chronic Obstructive Pulmonary Disease |
Chiesi Farmaceutici S.p.A. |
2011-04-12 | PHASE3 |
| NCT01315249 | COMPLETED | Chronic Obstructive Pulmonary Disease (COPD) |
Novartis Pharmaceuticals |
2011-03 | PHASE3 |
| NCT01323621 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2011-03-18 | PHASE3 |
| NCT01323634 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2011-03-18 | PHASE3 |
| NCT00395304 | COMPLETED | Asthma |
Milton S. Hershey Medical Center |
2007-03 | PHASE3 |
| NCT01342913 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2011-02-01 | PHASE3 |
| NCT01248975 | COMPLETED | Asthma |
GlaxoSmithKline |
2010-12 | PHASE2 |
| NCT01156792 | COMPLETED | Asthma |
GlaxoSmithKline |
2010-09 | PHASE2 |
| NCT01319019 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2010-12 | PHASE2 |
| NCT01181895 | COMPLETED | Asthma |
GlaxoSmithKline |
2010-09-01 | PHASE3 |
| NCT01147848 | COMPLETED | Asthma |
GlaxoSmithKline |
2010-06 | PHASE3 |
| NCT01494610 | COMPLETED | Asthma |
GlaxoSmithKline |
2010-10-25 | PHASE1; PHASE2 |
| NCT01124422 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2010-07-19 | PHASE4 |
| NCT00712335 | COMPLETED | Asthmatic Smokers; Non-asthmatic Smokers |
Inje University |
2007-02 | PHASE4 |
| NCT00595361 | COMPLETED | Asthma |
Brigham and Women's Hospital |
2008-01 | |
| NCT00914901 | UNKNOWN | Asthma |
Bispebjerg Hospital |
2009-07 | PHASE4 |
| NCT01243788 | UNKNOWN | Chronic Obstructive Pulmonary Disease (COPD) |
Fudan University |
2009-07 | PHASE4 |
| NCT00808288 | COMPLETED | Pulmonary Disease, Chronic Obstructive; Lung Diseases; Lung Diseases, Obstructive |
Pfizer |
2010-03 | PHASE2 |
| NCT01131806 | UNKNOWN | Chronic Obstructive Pulmonary Disease |
Taipei Veterans General Hospital, Taiwan |
2009-12 | PHASE4 |
| NCT00521222 | COMPLETED | Asthma |
Columbia University |
2007-06 | |
| NCT01388595 | COMPLETED | Allergic Rhinitis |
University of Dundee |
2006-11 | PHASE4 |
| NCT00876694 | COMPLETED | Chronic Obstructive Pulmonary Disease (COPD) |
Novartis Pharmaceuticals |
2009-03 | PHASE3 |
| NCT00741767 | WITHDRAWN | Chronic Obstructive Pulmonary Disease; Sleep Disorders |
Northwestern University |
2008-08 | |
| NCT00901368 | COMPLETED | Asthmatic Patients |
Chiesi Farmaceutici S.p.A. |
2009-05 | PHASE4 |
| NCT02136875 | COMPLETED | COPD; Chronic Obstructive Pulmonary Disease |
McGill University Health Centre/Research Institute of the McGill University Health Centre |
2008-07 | PHASE4 |
| NCT00984659 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2009-10-29 | PHASE4 |
| NCT00829257 | COMPLETED | Asthma |
University of Dundee |
2009-01 | PHASE4 |
| NCT01089127 | COMPLETED | Chronic Obstructive Pulmonary Disease |
Novartis Pharmaceuticals |
2010-03 | PHASE3 |
| NCT01079130 | COMPLETED | Asthma |
Novartis Pharmaceuticals |
2010-02 | PHASE3 |
| NCT01526161 | COMPLETED | Asthma |
Professor Warren Lenney |
2009-04 | PHASE4 |
| NCT00706446 | TERMINATED | Asthma |
Brigham and Women's Hospital |
2008-06 | |
| NCT01048333 | COMPLETED | Chronic Obstructive Pulmonary Disease |
AstraZeneca |
2010-01 | PHASE2 |
| NCT00830505 | COMPLETED | Asthma |
University of Dundee |
2009-04 | PHASE4 |
| NCT00565266 | COMPLETED | Asthma |
Milton S. Hershey Medical Center |
2008-05 | PHASE3 |
| NCT01186653 | COMPLETED | Chronic Obstructive Pulmonary Disease |
Hull University Teaching Hospitals NHS Trust |
2007-10 | PHASE4 |
| NCT00731770 | COMPLETED | COPD |
Milton S. Hershey Medical Center |
2009-01 | PHASE4 |
| NCT00563381 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
Boehringer Ingelheim |
2008-01 | PHASE4 |
| NCT00857766 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2009-03 | PHASE4 |
| NCT00864812 | COMPLETED | Chronic Obstructive Pulmonary Disease |
The Korean Academy of Tuberculosis and Respiratory Diseases |
2009-03 | PHASE4 |
| NCT00559312 | COMPLETED | COPD |
Queen's University |
2007-12 | |
| NCT00497237 | COMPLETED | Asthma |
Chiesi Farmaceutici S.p.A. |
2007-04 | PHASE3 |
| NCT00784550 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2008-12 | PHASE4 |
| NCT00927758 | COMPLETED | Asthma |
Sandoz |
2009-06 | PHASE2 |
| NCT01231230 | COMPLETED | Asthma |
University of Miami |
2007-05 | |
| NCT00908362 | COMPLETED | Smoke-related Lung Diseases; Chronic Obstructive Pulmonary Disease |
University of Rostock |
2009-05 | PHASE1 |
| NCT00821093 | COMPLETED | Chronic Obstructive Pulmonary Disease (COPD) |
Novartis Pharmaceuticals |
2009-01 | PHASE3 |
| NCT00531791 | COMPLETED | Chronic Obstructive Pulmonary Disease (COPD) |
Laval University |
2007-11 | PHASE3 |
| NCT00116402 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
University of Chicago |
2005-01 | PHASE1 |
| NCT00655616 | COMPLETED | Asthma |
University of Dundee |
2007-08 | |
| NCT00662792 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
Boehringer Ingelheim |
2008-04-15 | PHASE3 |
| NCT00527826 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2007-11 | PHASE4 |
| NCT00673478 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
Boehringer Ingelheim |
2008-05 | PHASE3 |
| NCT00452699 | COMPLETED | Asthma |
GlaxoSmithKline |
2007-05 | PHASE4 |
| NCT00452348 | COMPLETED | Asthma |
GlaxoSmithKline |
2007-05 | PHASE4 |
| NCT01271556 | COMPLETED | Salmeterol Effect Against an Acute Alveolar Fluid Clearance Challenge Secondary to Lung Fluid Overload in COPD Patients; Chronic Obstructive Pulmonary Disease; Bronchodilator Agents; Salmeterol |
University of Milan |
2008-12 | |
| NCT00633217 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2008-03 | PHASE4 |
| NCT00530842 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
Boehringer Ingelheim |
2007-09 | PHASE4 |
| NCT05459194 | COMPLETED | Asthma |
Elpen Pharmaceutical Co. Inc. |
2008-10 | |
| NCT00567996 | COMPLETED | Chronic Obstructive Pulmonary Disease (COPD) |
Novartis |
2007-11 | PHASE3 |
| NCT01255579 | COMPLETED | Bronchial Asthma |
Università degli Studi di Brescia |
2007-07 | PHASE4 |
| NCT00662740 | TERMINATED | Pulmonary Disease, Chronic Obstructive |
Boehringer Ingelheim |
2008-04-15 | PHASE3 |
| NCT00668772 | TERMINATED | Pulmonary Disease, Chronic Obstructive |
Boehringer Ingelheim |
2008-04-15 | PHASE3 |
| NCT00424008 | COMPLETED | Asthma |
Organon and Co |
2007-04 | PHASE3 |
| NCT00127166 | COMPLETED | Exercise Induced Asthma |
Organon and Co |
2005-12 | PHASE3 |
| NCT00197106 | COMPLETED | Asthma |
GlaxoSmithKline |
2005-06 | PHASE4 |
| NCT00640484 | COMPLETED | Chronic Obstructive Pulmonary Disease |
Chiesi Farmaceutici S.p.A. |
2008-04 | PHASE2 |
| NCT00350207 | COMPLETED | Asthma |
Boehringer Ingelheim |
2006-07 | PHASE2 |
| NCT00535366 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
Boehringer Ingelheim |
2007-10 | PHASE2 |
| NCT00542880 | COMPLETED | Chronic Obstructive Pulmonary Disease (COPD) |
AstraZeneca |
2007-09 | PHASE4 |
| NCT00669617 | COMPLETED | Chronic Obstructive Pulmonary Disease |
Novartis |
2008-04 | PHASE3 |
| NCT00529529 | COMPLETED | Asthma |
Novartis Pharmaceuticals |
2007-09 | PHASE3 |
| NCT01484210 | COMPLETED | Asthma |
Elpen Pharmaceutical Co. Inc. |
2008-03 | PHASE3 |
| NCT00615030 | COMPLETED | Chronic Obstructive Pulmonary Disease (COPD) |
Novartis |
2008-01 | PHASE3 |
| NCT00517634 | COMPLETED | Asthma |
GlaxoSmithKline |
2007-08 | PHASE4 |
| NCT00622635 | COMPLETED | Chronic Obstructive Pulmonary Disease |
Novartis Pharmaceuticals |
2008-01 | PHASE3 |
| NCT00503009 | TERMINATED | Asthma |
GlaxoSmithKline |
2007-10 | PHASE4 |
| NCT00531050 | COMPLETED | Chronic Obstructive Pulmonary Disease |
Novartis |
2007-08 | PHASE2 |
| NCT00478738 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2007-06 | PHASE2 |
| NCT00557440 | COMPLETED | Asthma |
Novartis |
2007-11 | PHASE2 |
| NCT00556673 | COMPLETED | Asthma |
Novartis |
2007-10 | PHASE2 |
| NCT00200967 | COMPLETED | Asthma |
Milton S. Hershey Medical Center |
2004-12 | PHASE3 |
| NCT00448435 | COMPLETED | Bronchial Asthma |
GlaxoSmithKline |
2007-04 | PHASE3 |
| NCT00441441 | COMPLETED | Asthma |
GlaxoSmithKline |
2007-02 | PHASE3 |
| NCT00214019 | COMPLETED | Allergic Asthma |
University of Wisconsin, Madison |
2003-11 | |
| NCT00461500 | COMPLETED | Asthma |
GlaxoSmithKline |
2007-03 | PHASE4 |
| NCT02318043 | COMPLETED | Asthma |
Guangzhou Institute of Respiratory Disease |
2007-01 | |
| NCT00403754 | COMPLETED | Asthma |
Novartis Pharmaceuticals |
2006-11 | PHASE2 |
| NCT00379288 | COMPLETED | Asthma |
Organon and Co |
2006-06 | PHASE3 |
| NCT00449046 | COMPLETED | Bronchial Asthma |
GlaxoSmithKline |
2007-03 | PHASE3 |
| NCT00296491 | COMPLETED | Asthma |
GlaxoSmithKline |
2005-09 | PHASE4 |
| NCT00355342 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2004-04-28 | PHASE4 |
| NCT00363480 | COMPLETED | Asthma |
GlaxoSmithKline |
2006-05-17 | PHASE4 |
| NCT00404261 | COMPLETED | Asthma |
GlaxoSmithKline |
2007-01 | PHASE4 |
| NCT00313209 | COMPLETED | Chronic Obstructive Pulmonary Disease (COPD) |
AstraZeneca |
2006-04 | PHASE3 |
| NCT00296530 | COMPLETED | Asthma |
GlaxoSmithKline |
2005-09 | PHASE4 |
| NCT00291382 | COMPLETED | Asthma |
GlaxoSmithKline |
2005-11 | PHASE4 |
| NCT00346749 | TERMINATED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2006-12 | PHASE4 |
| NCT00351143 | COMPLETED | Asthma |
GlaxoSmithKline |
2005-07-26 | PHASE4 |
| NCT00115492 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2004-12 | PHASE4 |
| NCT00605891 | COMPLETED | Chronic Obstructive Pulmonary Disease |
Chiesi Farmaceutici S.p.A. |
2006-10 | PHASE2 |
| NCT00372112 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2006-11-03 | PHASE2 |
| NCT00403286 | COMPLETED | Chronic Obstructive Pulmonary Disease |
Dey |
2006-11 | PHASE2 |
| NCT00422604 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2006-10 | PHASE2 |
| NCT00315744 | COMPLETED | Asthma |
GlaxoSmithKline |
2004-11-04 | PHASE4 |
| NCT00102765 | COMPLETED | Asthma |
GlaxoSmithKline |
2004-11 | PHASE4 |
| NCT00328718 | COMPLETED | Asthma |
GlaxoSmithKline |
2005-10 | PHASE3 |
| NCT00358358 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2006-03 | PHASE4 |
| NCT00347139 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2006-05-23 | PHASE2 |
| NCT00736801 | COMPLETED | Allergic Asthma |
University of Rostock |
2005-09 | |
| NCT00358488 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2006-04 | PHASE2 |
| NCT00102882 | COMPLETED | Asthma |
GlaxoSmithKline |
2004-10 | PHASE4 |
| NCT00144911 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2004-10 | PHASE4 |
| NCT00353873 | COMPLETED | Asthma |
GlaxoSmithKline |
2005-11-18 | PHASE4 |
| NCT00269087 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2005-01-28 | PHASE3 |
| NCT00245570 | COMPLETED | Asthma, Exercise-Induced |
Organon and Co |
2005-12 | PHASE3 |
| NCT00364273 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2005-08-24 | PHASE1 |
| NCT02254174 | COMPLETED | Healthy |
Boehringer Ingelheim |
2006-03 | PHASE1 |
| NCT00233051 | TERMINATED | Chronic Obstructive Pulmonary Disease (COPD); Emphysema; Chronic Bronchitis |
National Jewish Health |
2003-04 | |
| NCT00118716 | COMPLETED | Bronchospasm; Activity/Exercise Induced Bronchospasm |
GlaxoSmithKline |
2003-12-23 | PHASE4 |
| NCT00549146 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2003-11 | PHASE3 |
| NCT00361959 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2003-06 | PHASE4 |
| NCT02242227 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
Boehringer Ingelheim |
2005-09 | PHASE2 |
| NCT02238106 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
Boehringer Ingelheim |
2005-09 | PHASE2 |
| NCT00169546 | COMPLETED | Asthma |
GlaxoSmithKline |
2003-01 | PHASE4 |
| NCT00118690 | COMPLETED | Bronchospasm; Activity/Exercise Induced Bronchospasm |
GlaxoSmithKline |
2003-12 | PHASE4 |
| NCT00268216 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2000-09 | PHASE3 |
| NCT02256722 | COMPLETED | Healthy |
Boehringer Ingelheim |
2005-10 | PHASE1 |
| NCT02172794 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
Boehringer Ingelheim |
2002-05 | PHASE3 |
| NCT02254187 | COMPLETED | Healthy |
Boehringer Ingelheim |
2005-09 | PHASE1 |
| NCT00163358 | COMPLETED | Asthma |
AstraZeneca |
2003-09 | PHASE3 |
| NCT00480649 | COMPLETED | Asthma |
GlaxoSmithKline |
2004-01 | PHASE4 |
| NCT00269126 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2005-02 | PHASE3 |
| NCT00163488 | COMPLETED | Perennial Allergic Rhinitis; Allergic Rhinitis; Hay Fever |
AstraZeneca |
2005-01 | PHASE3 |
| NCT00156819 | COMPLETED | Asthma |
JHSPH Center for Clinical Trials |
2003-06 | PHASE4 |
| NCT00354874 | COMPLETED | Asthma |
GlaxoSmithKline |
2005-01 | PHASE2 |
| NCT00369993 | COMPLETED | Asthma |
GlaxoSmithKline |
2005-03 | PHASE2 |
| NCT00364442 | COMPLETED | Asthma |
GlaxoSmithKline |
2005-01-28 | PHASE1 |
| NCT00950794 | COMPLETED | Asthma; Bronchial Asthma |
GlaxoSmithKline |
2003-09 | PHASE4 |
| NCT02254226 | COMPLETED | Healthy |
Boehringer Ingelheim |
2004-11 | PHASE1 |
| NCT00064415 | COMPLETED | Chronic Obstructive Pulmonary Disease; Chronic Bronchitis; Emphysema |
Sumitomo Pharma America, Inc. |
2002-06 | PHASE3 |
| NCT01476059 | COMPLETED | Asthma |
GlaxoSmithKline |
2004-05 | PHASE4 |
| NCT00920543 | COMPLETED | Asthma |
GlaxoSmithKline |
2003-02 | PHASE4 |
| NCT00239421 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
Boehringer Ingelheim |
2003-11 | PHASE4 |
| NCT00239499 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
Boehringer Ingelheim |
2003-09 | PHASE4 |
| NCT00479739 | COMPLETED | Asthma |
GlaxoSmithKline |
2002-11 | PHASE4 |
| NCT02242253 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
Boehringer Ingelheim |
2003-09 | PHASE2 |
| NCT00370591 | COMPLETED | Asthma |
GlaxoSmithKline |
2002-12 | PHASE4 |
| NCT00064402 | COMPLETED | Chronic Obstructive Pulmonary Disease; Chronic Bronchitis; Emphysema |
Sumitomo Pharma America, Inc. |
2002-04 | PHASE3 |
| NCT00920959 | COMPLETED | Asthma |
GlaxoSmithKline |
2001-11 | PHASE3 |
| NCT00685841 | COMPLETED | COPD |
Sumitomo Pharma America, Inc. |
2002-02 | PHASE3 |
| NCT00274560 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
Boehringer Ingelheim |
2002-05-01 | PHASE3 |
| NCT02172287 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
Boehringer Ingelheim |
1999-02 | PHASE3 |
| NCT02173691 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
Boehringer Ingelheim |
1999-02 | PHASE3 |
| NCT00646594 | COMPLETED | Asthma |
AstraZeneca |
2003-11 | PHASE3 |
| NCT00158834 | COMPLETED | Asthma |
GlaxoSmithKline |
1999-11 | PHASE3 |
| NCT00471809 | TERMINATED | Asthma |
National Heart, Lung, and Blood Institute (NHLBI) |
2006-03 | PHASE4 |
| NCT00646009 | COMPLETED | Asthma |
AstraZeneca |
2003-03 | PHASE3 |
| NCT01202097 | COMPLETED | Asthma |
Eurofarma Laboratorios S.A. |
2011-08 | PHASE3 |
| NCT00525564 | COMPLETED | Chronic Obstructive Pulmonary Disease |
Laval University |
2006-05 | PHASE4 |
| NCT00646620 | COMPLETED | Asthma |
AstraZeneca |
2003-04 | PHASE3 |
| NCT00274534 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
Boehringer Ingelheim |
2000-12 | PHASE3 |
| NCT00394368 | COMPLETED | Bronchial Asthma |
Chiesi Farmaceutici S.p.A. |
2004-11 | PHASE3 |
| NCT00235053 | COMPLETED | Asthma; Candidiasis, Oral; Voice Disorders |
Allergy & Asthma Medical Group & Research Center |
2005-08 | PHASE4 |
| NCT00327353 | COMPLETED | Asthma |
GlaxoSmithKline |
2004-01 | PHASE4 |
| NCT00379028 | COMPLETED | Chronic Obstructive Pulmonary Disease |
AstraZeneca |
2006-09 | PHASE4 |
| NCT00273026 | TERMINATED | Asthma |
GlaxoSmithKline |
2004-11-08 | PHASE4 |
| NCT00400608 | COMPLETED | Asthma |
GlaxoSmithKline |
2006-10 | PHASE4 |
| NCT00158847 | TERMINATED | Chronic Obstructive Pulmonary Disease |
Leiden University Medical Center |
2000-04 | PHASE4 |
| NCT00411372 | WITHDRAWN | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2006-11 | PHASE3 |
| NCT00242775 | COMPLETED | Asthma |
AstraZeneca |
2005-05 | PHASE3 |
| NCT00468975 | COMPLETED | Asthma |
Pfizer |
2007-05 | PHASE2 |
| NCT00268177 | COMPLETED | Pulmonary Disease, Chronic Obstructive |
GlaxoSmithKline |
2002-10 | PHASE3 |
| NCT00252863 | COMPLETED | Asthma |
AstraZeneca |
2004-12 | PHASE3 |
| NCT00005110 | SUSPENDED | Cystic Fibrosis |
National Center for Research Resources (NCRR) |
(data from https://clinicaltrials.gov, updated on 2026-08-26)
Check the
Salmeterol
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Jump to
Note: Technical data last updated: Sep 1, 2026.